
Please try another search
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Jacqualyn A. Fouse | 61 | 2017 | Chair of the Board of Directors |
Brian M. Goff | 54 | 2022 | CEO & Director |
Kaye I. Foster-Cheek | 64 | 2014 | Lead Independent Director |
Jeffrey D. Capello | 59 | 2023 | Independent Director |
Cynthia Smith | 55 | 2022 | Independent Director |
Maykin Ho | 72 | 2015 | Independent Director |
David T. Scadden | 71 | 2017 | Independent Director |
Rahul D. Ballal | 47 | 2022 | Independent Director |
Catherine E. Owen Adams | 54 | 2023 | Independent Director |
Jay Thomas Backstrom | 70 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review